Physician profile
Matthew A Berger
NPI 1295718237
$1,679,904.74
in general payments reported to CMS, 2019-2025
41 companies · $318K in 2025
The $318K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187K · 2020: $87K · 2021: $161K · 2022: $221K · 2023: $352K · 2024: $354K · 2025: $318K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $728K · Consulting Fee: $151K · Travel and Lodging: $102K · Food and Beverage: $21K · Honoraria: $17K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,000 · Education: $536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $728,023.38 |
| Consulting Fee | $151,471.25 |
| Travel and Lodging | $102,193.62 |
| Food and Beverage | $21,248.85 |
| Honoraria | $16,775.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,000.00 |
| Education | $536.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $377,958.47 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $320,792.60 | 2019-2025 | Rexulti, Nuedexta |
| Neurocrine Biosciences, INC. | $278,304.44 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $159,299.25 | 2022-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $132,463.01 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $112,029.17 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $83,407.63 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Vanda Pharmaceuticals INC. | $77,514.91 | 2020-2025 | Fanapt |
| Eisai INC. | $29,129.99 | 2020-2024 | |
| Abbvie INC. | $28,718.31 | 2021-2025 | Vraylar |
| Allergan, INC. | $17,798.08 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $17,700.28 | 2022-2023 | Quviviq |
| Biogen, INC. | $10,387.10 | 2020-2025 | Zurzuvae, Leqembi |
| Sunovion Pharmaceuticals INC. | $9,619.33 | 2019-2020 | |
| Sage Therapeutics, LLC | $9,448.70 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $3,810.29 | 2019-2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $2,571.98 | 2024-2025 | Cobenfy |
| Neuronetics, INC. | $2,526.40 | 2019-2024 | Neurostar Tms Therapy System |
| Livanova USA, INC. | $2,197.70 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Bioxcel Therapeutics, INC. | $1,215.00 | 2023 | Igalmi |
| Alfasigma USA, INC. | $1,075.56 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $436.13 | 2019-2023 | |
| Bausch Health US, LLC | $281.32 | 2020-2024 | Wellbutrin, Aplenzin |
| Indivior INC. | $215.97 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $186.92 | 2020-2023 | Belsomra |
| Neos Therapeutics, Lp | $138.29 | 2020-2024 | Adzenys Xr-Odt |
| Novo Nordisk INC | $131.21 | 2023-2025 | Wegovy |
| Almatica Pharma LLC | $120.70 | 2022-2025 | Loreev Xr |
| Acadia Pharmaceuticals INC | $101.83 | 2019-2022 | |
| Lundbeck LLC | $99.78 | 2020-2021 | |
| Corium, LLC | $54.54 | 2023-2025 | Azstarys |
| Avanir Pharmaceuticals, INC. | $52.18 | 2020-2022 | |
| Harmony Biosciences LLC | $49.29 | 2020 | |
| Sun Pharmaceutical Industries INC. | $19.76 | 2021 | |
| Owp Pharmaceuticals, INC. | $17.50 | 2021 | |
| Adlon Therapeutics L.P. | $16.30 | 2020 | |
| Ironshore Pharmaceuticals INC. | $14.82 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.